FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVIB APPROVAL											
OMB Number:	3235-0287										
Estimated average burd	len										
hours ner resnonse:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar Swishe (Last) C/O COM	- <u>C(</u>	Susuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] Date of Earliest Transaction (Month/Day/Year) 06/02/2021									Relationship of Reporting Person(s) to Is leck all applicable) X Director 10% O Officer (give title below) below)				vner				
INCORPORATED 149 COMMONWEALTH DRIVE (Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
l` ′	PARK (94025 (Zip)		_										Form filed by More than One Reporting Person				
		Tab	le I - N	on-Deri	vative	Sec	urit	ies Ac	quired	l, Di	isposed o	of, or Be	neficia	lly O	wned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/)					ction	on 2A. Deemed Execution Date,		3. 4. Securiti		es Acquired (A) or Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	V Amount (A) C		(A) or (D)	Price	1	Transac (Instr. 3	tion(s)			,5 4)
Common Stock 06/02/20						21			M ⁽¹⁾		7,500) A \$6.5		5	7,500		D		
Common Stock 06/02/202					2021)21			S ⁽¹⁾		7,500	D	\$21.47	21.478 ⁽²⁾		0		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Deri	rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares	per					
Stock Option (Right to Buy)	\$6.55	06/02/2021			M ⁽¹⁾			7,500	(3)		06/18/2025	Common Stock	7,500	\$(0.00	35,000		D	

Explanation of Responses:

- 1. The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- 2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$21.33 to \$21.59 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from Issuer upon request.
- 3. Fully exercisable.

Remarks:

/s/ Joseph Douglas Lyon, Attorney-in-Fact for Daniel N. 06/04/2021 Swisher, Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.